Research at the Parsons Lab
PARSONS LAB MISSION
The Parsons Laboratory fosters and conducts innovative research to develop and implement novel blood biopsy technologies to decrease under- and over-treatment of breast cancer and to deliver correct therapies to those who need them most.
RESEARCH PROGRAM
Historically, clinical tests, including liquid biopsy, have not required nearly the same level of evidence to use in patients as medicines.
What do we do?
Fundamentally, we are working to improve the length and quality of life of patients living with breast cancer. Each study we lead aims to bring liquid biopsy from the lab to the clinic, with rigorous evidence to support the link. We collaborate closely with basic scientists and technology developers to bring promising biomarkers from the lab to the clinic. We lead clinical studies to understand biomarkers in patients with early and advanced breast cancer and to assess the clinical utility of liquid biopsy in patients with breast cancer. We lead clinical trials to figure out whether using liquid biopsy in patients makes a difference for them: improving and lengthening patients’ lives.
What do we do?
Fundamentally, we are working to improve the length and quality of life of patients living with breast cancer. Each study we lead aims to bring liquid biopsy from the lab to the clinic, with rigorous evidence to support the link. We collaborate closely with basic scientists and technology developers to bring promising biomarkers from the lab to the clinic. We lead clinical studies to understand biomarkers in patients with early and advanced breast cancer and to assess the clinical utility of liquid biopsy in patients with breast cancer. We lead clinical trials to figure out whether using liquid biopsy in patients makes a difference for them: improving and lengthening patients’ lives.
HOME | RESEARCH | PEOPLE | PUBLICATIONS | FUNDING | CONTACT | SUPPORT
©2022 Parsons Lab at Dana-Farber Cancer Institute
©2022 Parsons Lab at Dana-Farber Cancer Institute